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creativecommons.org/licenses/by/4.0/).AIM: To estimate and compare the extent of myeloma bone disease by skeletal region using
whole-body diffusion-weighted imaging (WB-DWI) and skeletal survey (SS) and record
interobserver agreement, and to investigate differences in imaging assessments of disease
extent and apparent diffusion coefﬁcient (ADC) between patients with pathological high
versus low disease burden.
MATERIALS AND METHODS: Twenty patients with relapsed myeloma underwent WB-DWI
and SS. Lesions were scored by number and size for each skeletal region by two indepen-
dent observers using WB-DWI and SS. Observer scores, ADC, and ADC-deﬁned volume of
tumour-inﬁltrated marrow were compared between patients with high and low disease
burden (assessed by serum paraproteins and marrow biopsy).
RESULTS: Observer scores were higher on WB-DWI than SS in every region (p<0.05) except
the skull, with greater interobserver reliability in rating the whole skeleton (WB-DWI:
ICC ¼ 0.74, 95% CI: 0.443e0.886; SS: ICC ¼ 0.44, 95% CI: 0.002e0.730) and individual body
regions. WB-DWI scores were not signiﬁcantly higher in patients with high versus low disease
burden (observer 1: mean  SD: 48.8  7, 38.6  14.5, observer 2: mean  SD: 37.3  13.5,
30.4  15.5; p ¼ 0.06, p ¼ 0.35).
CONCLUSION: WB-DWI demonstrated more lesions than SS in all regions except the skull
with greater interobserver agreement. Sensitivity is not a limiting factor when considering
WB-DWI in the management pathway of patients with myeloma.
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In myeloma, a plasma cell disease with diffuse or focal
marrow inﬁltration, skeletal involvement is often hetero-
geneous and variable.1,2 Disease burden is assessed by
serum markers and bone trephine,3 but these tests are not
always reliable: bone trephine is prone to sampling error
and neither test provides information on the extent and
distribution of disease. In asymptomatic patients the skel-
eton is imaged with a skeletal survey (SS) as bone disease is
a criterion of symptomatic myeloma that requires treat-
ment.4 However, despite the low sensitivity of SS, which is
limited to imaging the secondary effects of disease on
cortical bone,5e9 its low cost and widespread availability
mean that it remains the recommendation of the Interna-
tional Myeloma Working Group (IMWG) as a ﬁrst-line
screen for bone involvement.1,10,11 For patients with bone
pain, some centres are substituting skeletal survey with
whole-body low-dose CT, but due to limited contrast within
the marrow itself, this too lacks sensitivity.12e14 Current
guidelines suggest MRI of the spine in asymptomatic pa-
tients where SS or CT are negative and a positive MRI in an
asymptomatic patient is increasingly recognized as an
indication to treat.15e17
Whole-body diffusion-weighted MRI (WB-DWI) is now
recognized as a promising clinical tool because it can pro-
vide information on differences between normal and
diseased bone marrow microarchitecture18 for the entire
skeleton in a 25 min time frame. Signiﬁcant differences in
the measured marrow apparent diffusion coefﬁcient (ADC)
between normal subjects and myeloma patients18,19 and
between patients with active myeloma and those in
remission20 have been demonstrated. Because it provides a
means of quantiﬁcation, WB-DWI in myeloma also has been
explored as a measure of response.21 The only other quan-
titative imaging technique investigated in myeloma
is18FDG-PET/CT, sensitivity and speciﬁcity of which is infe-
rior to even conventional MRI1,22,23 with skull and rib le-
sions poorly demonstrated in both cases.24 In addition,
18FDG-PET/CT carries a signiﬁcant cost implication as well
as a radiation dose. This makes WB-DWI potentially more
attractive for staging and response assessment because not
only can disease be assessed by skeletal region, but it can
also be related to pathological disease burden. Therefore,
the aims of the present study were to estimate and compare
the extent of myeloma bone disease by skeletal region using
WB-DWI and SS, assess interobserver agreement of both
techniques, and investigate differences in imaging assess-
ments of disease extent and ADC between patients with a
pathological high versus low disease burden.Materials and methods
This was a prospective, HIPAA (Health Insurance Porta-
bility and Accountability Act) compliant, single-institution
study with approval from the local Research Ethics Com-
mittee. Written informed consent was obtained from each
patient.Patients and volunteers
Twenty patients with relapsed active myeloma (aged
45e73 years, eight male, 12 female) underwent WB-DWI
and SS prior to starting treatment. Patients with relapsed
myeloma were recruited in order to ensure the presence of
active disease at multiple skeletal sites. Patients with sus-
pected spinal cord compression or contra-indications to
MRI were excluded. Serum paraproteins, light chains, and
bone marrow histology were recorded to assess patients’
pathological disease burden, deﬁned according to current
guidelines.11 Patients were classiﬁed as having a high
burden of disease if there was 50% inﬁltration of plasma
cells on bone marrow trephine; otherwise they were clas-
siﬁed as low burden of disease. Clinical characteristics of the
patients, including the presence or absence of CRAB fea-
tures (hypercalcaemia: corrected serum calcium
>0.25mmol/l above upper limit of normal or>2.75mmol/l;
renal insufﬁciency: serum creatinine >173 mmol/l;
anaemia: haemoglobin 2 g/dl below lower limit of normal
or <10 g/dl; bone lesions: present),25 are summarized in
Table 1. Follow-up laboratory assessments after three cycles
of treatment showed a response to treatment in 14 of 20
patients and progressive disease in three of 20 (classiﬁed
according to the IMWG uniform response criteria),3 con-
ﬁrming active disease at the outset. In the remaining three
patients with stable disease, changes in serum paraproteins
did not reach criteria for partial response or progressive
disease.Image acquisition
Using an Avanto 1.5 T system (Siemens, Erlangen, Ger-
many) a WB study was achieved by the serial acquisition of
contiguous body regions. All participants were scanned
supine with arms by their sides. Coil elements were posi-
tioned from skull vertex to knees. Axial T1-weighted (W)
spin-echo [5 mm section thickness, no gap, 430 mm ﬁeld of
view (FOV), anteroposterior (AP) phase direction, 386 ms
repetition time (TR)/ 4.8 ms echo time (TE), 70 ﬂip angle,
256 154matrix] and coronal VIBE Dixon 3D gradient-echo
breath-hold sequences (52 sections per slab, 470 mm FOV,
7 ms TR/2.38,4.76 ms TE, 3 ﬂip angle, 192  192 matrix)
were acquired, followed by axial DW sequences [single-shot
double spin-echo echo-planar technique with short tau
inversion recovery (STIR) fat suppression in free breathing].
b-Values of 50 and 900 s/mm2 were applied in three
orthogonal directions and combined to provide isotropic
trace images. DW sequences were acquired in blocks of 50
sections (5 mm section thickness, no gap, 430 mm FOV, AP
phase direction, parallel imaging (GRAPPA) factor 2,
14,800 ms TR, 66 ms TE, 180 ms inversion time (TI),
2.9  2.9  5 mm voxel size, four signal averages acquired,
150  150 matrix, 1960 Hz per pixel bandwidth). The opti-
mized scanner carrier frequency offset used for the top
station was applied for all other stations.26 The same shim
gradient currents were applied for each station.27 Total
acquisition time was 50e60 min.
Table 1
Clinical characteristics of the patients, indicating the degree of marrow inﬁltration on bonemarrow trephine, serum paraprotein and light chain concentrations,
and the range of CRAB features present in this cohort.
Patient
no.
Age
(years)
Sex Myeloma type Affected cells
on BMT (%)
Serum
M-protein
(g/l)
Serum free
k (mg/l)
Serum
free l
(mg/l)
Corrected serum
Calcium (mmol/l)
Serum
creatinine
(mmol/l)
Haemoglobin
(g/dl)
Bone
lesions
1 61 M Non Secretory 60 0 <6 5 2.19 70 12.2 N
2 65 F k light chain 80 0 2100 <5 2.41 77 9.3 Y
3 70 F IgG k 25 13 1175 <5 2.20 55 12.9 Y
4 72 F IgG k 20-25 20 ND ND 2.40 78 14.0 N
5 61 M IgG k ND 13 56 <5 2.24 104 8.4 Y
6 67 M IgA l 25-35 37 10 5000 2.50 262 10.1 Y
7 60 F IgG l 2-5 6 <4 37 2.31 51 12.8 N
8 67 M IgG k 80 8 15 9 2.30 136 13.8 Y
9 65 M IgG l 10-20 0 7 1275 2.16 87 12.4 Y
10 55 F l light chain 20-30 0 7 650 2.44 59 11.2 Y
11 62 F IgG k 25 13 ND ND 2.30 65 11.6 N
12 65 F IgG k 60-70 49 ND ND 2.28 83 10.4 Y
13 68 F IgG k 10-20 28 ND ND 2.29 63 10.6 Y
14 68 M IgG k 60 39 625 6 2.61 82 11.6 Y
15 73 M IgG k ND 26 ND ND 1.96 272 9.2 Y
16 47 M IgG k 30-40 10 ND ND 2.18 50 13.3 Y
17 68 F IgG l 40-50 23 ND ND 2.23 40 13.1 Y
18 45 F IgG l 70-80 28 <4 130 2.17 58 10.4 Y
19 47 F IgG k 30-40 35 ND ND 2.42 60 11.4 N
20 69 F IgG k 10-15 23 ND ND 2.32 116 9.9 Y
CRAB: Hypercalcaemia deﬁned as corrected serum calcium >0.25 mmol/l above upper limit of normal or >2.75 mmol/l; renal insufﬁciency if serum creatinine
>173 mmol/l; anaemia if haemoglobin 2 g/dl below lower limit of normal or <10 g/dl; bone lesions deﬁned by  1 lytic lesion seen on SS departmental report.
BMT, bone marrow trephine; ND, no data.
S.L. Giles et al. / Clinical Radiology 70 (2015) 614e621616SS radiographs were acquired using a Carestream Digital
Radiography system (Rochester, NY, USA) and consisted of
the following series of projections: lateral skull, poster-
oanterior (PA) chest, AP pelvis, AP and lateral cervical (C),
thoracic (T) and lumbar (L) spines, AP humerii, AP femora.Image analyses
Morphological images were checked for the presence of
fractures and other benign lesions, such as signiﬁcant
vertebral haemangiomas, which have the potential to affect
the diffusion-weighted signal. No such lesions were noted
in this small cohort.
Observer scores
For each body region (skull, C spine, T spine, L spine,
pelvis, ribs/other, long bones) two radiologists (C.M. and
N.D.S.) with 7 years of experience of DWI in bone (blinded
to clinical information) made a categorization of disease
burden with a previously used scoring system.21 This was
based on number of lesions (diffuse, >20, 10e20, <10, 0)
and largest lesion dimension (diffuse,>10, 5e10,<5, 0 mm)
on WB-DW images, assigning a score from 4 to 0 for each
characteristic (lesion number and size).21 Images provided
were b ¼ 50 s/mm2 and b ¼ 900 s/mm2 source images, ADC
maps and composed WB-DW inverted greyscale maximum
intensity projection (MIP) b ¼ 900 s/mm2 images. All im-
ages were reviewed in conjunction as T2 shine through
from old inactive sites at b ¼ 900 s/mm2 can mimic cellular
active disease. On a separate occasion, at least 2 weeks
apart, the same two observers used the same system to
categorize lesions observed on SS. The same image scoringsystemwas then applied to each categorization, so that the
possible score for each body region on WB-DWI and SS
ranged from 8-0, (56-0 for the whole skeleton).
ADC derivation
Quantitative ADC analysis was undertaken using Onco-
Treat software (Siemens, Erlangen, Germany). Multiple
volumetric regions of interest were outlined against three-
dimensional multiplanar reformatted (MPR) images of the
b ¼ 900 s/mm2 data using a semi-automated technique,
whereby one set of “seeds” was manually placed inside
every region to be included in the analyses, with a second
set being deﬁned to exclude surrounding areas. The soft-
ware then generated outlines of volumes to be included in
the segmentation, based on signal intensity values. Seg-
mentations included all areas of visible marrow within
vertebral bodies, pelvis, femora, proximal humeri, and
sternum, and were undertaken by one observer (S.G.). ADC
values for every voxel within the segmented volume were
recorded and displayed as histograms. The volume of
tumour inﬁltrated marrow was deﬁned by recording every
voxel with an ADC 774 but 1433 mm2/s18,28 and
compared against laboratory measures of disease burden.Statistical analyses
Comparison of WB-DWI and SS
Paired t-tests were used to evaluate whether each
observer assessed that WB-DWI scores were signiﬁcantly
different from SS scores by body region and per patient. A
value of p<0.05 was chosen as the criterion for statistical
signiﬁcance in all tests. Scores assigned to WB-DWI and SS
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intraclass correlation coefﬁcient (ICC) for interobserver
reliability for whole skeleton and individual body areas
using MedCalc software (Version 14.12.0, Ostend, Belgium).
Comparison of imaging and pathological estimates of
disease burden
Normality plots and the KolmogoroveSmirnov and
ShapiroeWilk tests were used to conﬁrm normality using
SPSS for Windows software (Version 20, SPSS, IBM, New
York, NY, USA). Independent samples t-tests were used to
determine whether the distribution of observer scores, ADC
metrics, and tumour volume were different in patients with
a high or low disease burden. In addition, Pearson’s corre-
lation coefﬁcients were calculated to evaluate the strength
of any relationship between observer scores, measured ADC
metrics, and laboratory measures of disease burden in the
patients.
Results
Comparison of WB-DWI and SS
Observer scores for WB-DWI and SS for whole skeleton
and by body region are given in Table 2. For observer 1, WB-
DWI scores were higher than SS scores in 16 of 20 patients,
equivalent for two patients and lower in two patients. For
observer 2, WB-DWI scores were higher than SS scores in 19
of 20 patients and lower in one patient. When assessed by
region, both observers scored WB-DWI signiﬁcantly more
highly than SS in every region (p<0.05) except the skull,
where observer 1 scored DWI more highly (p ¼ 0.03) but
observer 2 did not (p ¼ 0.8). There were signiﬁcantly more
patients with a positive score (>0) in each region outside
the skull onWB-DWI than on SS for both observers (Table 3,
Fig 1). There was greater interobserver reliability in rating
WB-DWI than SS scores when assessed for the whole
skeleton (WB-DWI: ICC ¼ 0.74, 95% CI: 0.443e0.886; SS:
ICC ¼ 0.44, 95% CI: 0.002e0.730) or by region (Table 4).
Comparison of imaging and pathological estimates of
disease burden
Of the 20 patients, six were classiﬁed as having a high
burden of disease and 12 as low burden (in two patientsTable 2
Observer scores for whole-body diffusion-weighted imaging (WB-DWI) were sign
every body region outside of the skull.
Region
Observer 1 scores
(mean  SD)
O
(m
WB-DWI SS W
Skull 5.3  3.5 3.1  2.3 2
C spine 5.8  2.7 3.3  3.5 4
D spine 6.9  1.9 5.2  3.5 6
L spine 6.5  2.1 3.8  3.6 4
Pelvis 5.8  2.6 2.4  2.9 5
Ribs/other 7.3  1.3 2.8  2.7 6
Long bones 5.4  2.8 2.1  2.0 4
Whole skeleton 42.4  12.8 22.2  15.5 33bone marrow samples were unquantiﬁable). None of the
patients had a raised serum calcium level; two exhibited
renal insufﬁciency (one in the low disease burden group
and one where there was no quantiﬁed bone marrow
sample), and ﬁve were anaemic (one high burden of dis-
ease, two low burden of disease, two unquantiﬁed samples).
Observer scores
Mean WB-DWI scores per patient were higher in those
with a high burden of disease than in those with a low
burden of disease (observer 1: mean  SD: 48.8  7,
38.6 14.5; observer 2: mean SD: 37.313.5, 30.415.5;
Figs 2e3), but these differences did not achieve statistical
signiﬁcance (p ¼ 0.06, p¼ 0.35 respectively). SS scores were
also higher in thosewith a high burden of disease compared
to thosewith a lower burden for both observers (observer 1:
mean  SD 30.2  14.5, 15.1 12.8; observer 2: mean  SD
14  9.3, 7.1  6.3), but also did not achieve statistical sig-
niﬁcance (p¼ 0.06, p¼ 0.142 respectively). There were no
signiﬁcant correlations between WB-DWI observer scores
and the proportion of plasma cells on bone marrow
trephine (observer 1: r ¼ 0.378, p¼ 0.122; observer 2:
r ¼ 0.227, p¼ 0.366) or betweenWB-DWI scores and serum
paraprotein concentration (observer 1: r¼ 0.443, p¼ 0.086;
observer 2: r ¼ 0.474, p¼ 0.064).
ADC analysis
Two patients were not evaluable by ADC: in one the WB-
DWI was severely degraded by artefacts, and in the other
lack of visible bone marrow precluded successful segmen-
tation. Mean marrow ADC for the whole segmented volume
in each patient ranged from 659e971  106 mm2/s
(mean  SD 802  89  106 mm2/s). Volume of marrow
segmented in the patients ranged from 135e1338 cm3
(mean  SD: 650  342 cm3). The volume of tumour inﬁl-
trated marrow ranged from 35e555 cm3 (mean  SD:
241  155 cm3). There were no signiﬁcant differences in
mean ADC or volume of tumour inﬁltrated marrow be-
tween those classiﬁed with a low or high disease burden
(p¼ 0.97, p¼ 0.80 respectively). In addition, there was no
signiﬁcant correlation between mean ADC or the
segmented tumour volume and the proportion of plasma
cells on bonemarrow trephine (r¼e0.1, p¼ 0.72, r¼e0.04,
p¼ 0.88) or with serum paraprotein concentration
(r ¼ e0.2, p¼ 0.52, r ¼ 0.16, p¼ 0.59).iﬁcantly higher than for x-ray skeletal survey (SS) for whole skeleton and in
bserver 2 scores
ean  SD)
WB-DWI & SS
Paired t-test (p)
B-DWI SS Obs 1 Obs 2
.3  2.9 2.5  1.6 0.03 0.83
.6  3.3 0.7  1.2 0.04 <0.0001
.5  2.1 0.8  1.6 0.04 <0.0001
.8  3.2 1.0  1.4 0.003 0.0002
.1  2.7 1.4  1.9 0.0001 <0.0001
.1  3.0 1.3  1.7 <0.0001 <0.0001
.9  2.9 1.7  1.6 0.0002 0.0001
.9  14.4 9.1  7.7 <0.0001 <0.0001
Table 3
Patients scored positively on whole-body diffusion-weighted imaging (WB-DWI) and x-ray skeletal survey (SS) by each observer, by body region.
Region
Observer 1
% pts scoring positively (no. pts)
Observer 2
% pts scoring positively (no. pts)
WB-DWI SS % Difference
WB-SS
WB-DWI SS % Difference
WB-SS
Skull 75 (15) 75 (15) 0 55 (11) 80 (16) -25
C spine 95 (19) 60 (12) 35 80 (16) 35 (7) 45
D spine 100 (20) 75 (15) 25 100 (20) 20 (4) 80
L spine 95 (19) 60 (12) 35 95 (19) 35 (7) 60
Pelvis 90 (18) 50 (10) 40 90 (18) 40 (8) 50
Ribs/other 100 (20) 65 (13) 35 85 (17) 40 (8) 45
Long bones 85 (17) 65 (13) 20 85 (17) 60 (12) 25
Whole skeleton 100 (20) 85 (17) 15 100 (20) 85 (17) 15
Pts, points.
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The present study demonstrates increased scores
derived fromWB-DWI compared to SS in all skeletal regions
except the skull and highlights the increased sensitivity of
WB-DWI. Although histological veriﬁcation that the addi-
tionally detected lesions represent active sites is not
feasible, other studies with histological validation have
shown that lesions detected bymodern imaging techniques
do represent active myeloma bone lesions.24 Outside the
skull, sites detected on SS are not missed on WB-DWI. This
builds on other data comparing T1W and T2W MRI with SS
where MRI showed increased sensitivity.29e31 The addi-
tional advantage of WB-DWI is its demonstration of more
lesions in the ribs, long bones, and shoulders compared to
SS.24 WB-DWI provides additional advantages in being able
to detect extramedullary soft-tissue disease (although none
was found in the present series) and to age vertebral
compression fractures as both the b ¼ 50s/mm2 images and
ADC maps can be used to detect oedema.
In common with other studies,24,31,32 DWI appeared less
sensitive than SS to detect disease in the skull, possibly due
to obscuration from the diffusion restriction from the brain.
It is also feasible that cases where SS was positive and DWI
negative represented ﬁxed cortical defects from old treated
disease (as the present cohort all had relapsed disease) orFigure 1 Images of the chest in a 65-year-old female patient with non-se
images and (b) chest radiograph. Numerous discrete focal lesions are visu
radiograph.prominent venous lakes. The improved observer reliability
in rating WB-DWI than SS scores did not apply in the skull,
partly because there were ﬁve patients in whom observer 1
rated diffuse disease in the skull but observer 2 rated no
disease. The only other region inwhich agreement in scores
was lower on DWI than SS was in the ribs, although there
was agreement in the presence or absence of disease in 17
of 20 patients on DWI and in only eight of 20 on SS. Greater
experience of WB-DWI is likely to improve results further,
unlike SS where observer agreement remains a limitation of
the technique despite years of experienced interpretation.7
Furthermore, the conventional MRI that is also acquired as
part of the total WB examination provides additional in-
formation to complement the DWI, improve diagnostic
conﬁdence, and reduce false-positive ﬁndings from benign
lesions, e.g., haemangiomas.
In the event of equivocal ﬁndings on WB MRI, the lack of
any ionizing radiation makes it reasonable to acquire an
interval scan for clariﬁcation. In contrast, a typical SS may
confer a dose of approximately 1.8 mSv each time for each
patient33; therefore, representing a signiﬁcant potential
total dose if used on a serial basis. Unfortunately, the cost of
aWBMRI examination remains signiﬁcantly higher than SS.
However, as WB-DWI techniques develop, it is anticipated
that sequence acquisition times will reduce and the degree
of automated post-processing of images will increase,cretory myeloma shown by (a) inverted greyscale b ¼ 900 s/mm2 DW
alized in the ribs on the DWI, which are not easily seen on the chest
Table 4
Inter-observer reliability in rating whole-body diffusion-weighted imaging
(WB-DWI) and x-ray skeletal survey (SS) scores by body area and for whole
skeleton.
Region
Inter-observer reliability(ICC
[95% Conﬁdence Interval])
WB-DWI SS
Skull 0.22
[-0.245 to 0.607]
0.75
[0.463 to 0.897]
C Spine 0.77
[0.490 to 0.903]
0.174
[-0.292 to 0.574]
D Spine 0.34
[-0.110 to 0.673]
0.18
[-0.273 to 0.570]
L Spine 0.49
[0.069 to 0.760]
0.26
[-0.190 to 0.625]
Pelvis 0.48
[0.058 to 0.755]
0.47
[0.044 to 0.749]
Ribs/Other 0.40
[-0.037 to 0.711]
0.63
[0.270 to 0.835]
Long Bones 0.78
[0.524 to 0.907]
0.55
[0.160 to 0.796]
Whole Skeleton 0.74
[0.443 to 0.886]
0.44
[0.003 to 0.730]
Figure 2 Inverted greyscale b ¼ 900 s/mm2 WB-DW images in a 65-
year-old female patient with myeloma and a high disease burden of
70% clonal cells on bone marrow biopsy (note right femoral nail).
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DWI.
The differences in WB-DWI scores between those with a
high burden of disease, compared to those with a low
burden of disease at histopathology were limited by histo-
pathological validation from a single biopsy site. Previous
studies have shown that ADC can be used to differentiate
patients with active myeloma from those in remission.20
However, the failure to demonstrate a signiﬁcant relation-
ship between ADC and laboratory measures of disease
burden may well reﬂect the overlap between the ADC
values of diffuse disease and normal marrow, compared to
the greater distinction between focal disease and normal
marrow.18 In addition, the laboratory measures of disease
burden may not be representative of the extent or histo-
logical severity of disease,34 because of the sampling error
and serum markers are not always reliable. Other contrib-
uting factors to the lack of difference in ADC between high
and low pathology disease burden groups is the small size
of the patient cohort as well as the uncharacterized effects
of previous treatments. Further study of a larger cohort of
patients, or of those newly diagnosed and not exposed to
previous treatments, may help to clarify any differences
between ADC in different pathological classes.
A limitation of the present evaluation is the lack of a
universally accepted scoring system. Various methods have
been described: Bannas et al.35 deﬁned imaging response
categories based on changes in size or number of lesions,
whereas Hillengass et al.36 assessed both the number of
focal lesions and the degree of diffuse inﬁltration. In the
present study a scoring system that incorporated both of
these elements was utilized.21 However, the authors’
experience over the last 4 years has been that qualitative
analysis alone is usually sufﬁcient to assess the presence
and extent of myeloma bone disease using WB-DWI, with
quantitative analyses offering some advantages for assess-
ing response to treatment.21A limitation of the present ADC analyses is the resolution
of the segmentation method chosen, where the most sig-
niﬁcant factor was lack of contrast in the b ¼ 900 s/mm2
images in patients with little active disease. Not only was
seed placement more difﬁcult, but the subsequently
generated outlines of the segmentations conformed less
tightly to the borders of the bony anatomy than in patients
with higher contrast images. This meant that some pixels
included within the segmentations probably lay outside the
target anatomy when image contrast was poor. In addition,
the ribs were not included in the segmentations due to the
complexity of deﬁning seeds to separate each rib accurately
and the processing power of the software. Therefore, in
some patients with the highest burden of disease, or in
those with disease in the ribs, the segmentation may not
have been truly representative. One method for addressing
this would be to deﬁne smaller volumes as separate
Figure 3 Inverted greyscale b ¼ 900 s/mm2 WB-DW images in a 60-
year-old female myeloma patient with myeloma and a low disease
burden of 5% clonal cells. Note the lower signal-intensity in the
skeleton compared to Fig. 2.
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other structure separately, but this could be very time
consuming, requiring improvements in speed of software or
the degree of automation to be a viable clinical option for
analysing data. It is also possible that the ADC range deﬁned
by Padhani et al.28 to represent myeloma inﬁltratedmarrow
(774e1433  106 mm2/s) was inappropriate for this
volumetric segmentationmethod of ADC analysis. However,
the present DWI acquisition strategy was very similar to
that used by Padhani et al.28 and the mean  SD marrow
ADC for the myeloma patients in the present study
(802.2  89.1  106 mm2/s) was comparable
(875  187  106 mm2/s). Furthermore, inspection of the
present data revealed that applying other thresholds to
deﬁne the tumour inﬁltrated marrow did not elicit any
further signiﬁcant ﬁndings.In conclusion, the present study shows that WB-DWI
demonstrates a greater extent of disease in myeloma pa-
tients than SS in every body region except the skull. More
lesions were also seen in the ribs on DWI than SS, which has
previously been a limitation of conventional MRI tech-
niques. The improved interobserver reliability afforded by
WB-DWI in the present study is also an important ﬁnding,
although there is still room for improvement as experience
with the technique grows. The role of WB-DWI in the
routine investigation of patients with myeloma has not
been established but the signiﬁcant promise for imaging
and quantifying response to treatment21 is likely to lead to
further trials. This study indicates that sensitivitywill not be
a limiting factor when considering WB-DWI in the man-
agement pathway of patients with myeloma.
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